Business Context and Reporting Period
Company: Autonomix Medical, Inc. (AMIX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended December 31, 2025
Business Overview: A pre-revenue, clinical-stage medical device company developing a proprietary platform for sensing and treating disorders of the peripheral nervous system. The lead technology is a catheter-based system combining diagnostic sensing and therapeutic radiofrequency ablation, initially targeting pancreatic cancer pain.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 31, 2025 | Nine Months Ended Dec 31, 2025 | Balance Sheet (Dec 31, 2025) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(3,261) | $(14,049) | N/A |
| Operating Expenses | $(3,343) | $(14,297) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $9,934 |
| Working Capital | N/A | N/A | $8,541 |
| Accumulated Deficit | N/A | N/A | $(64,427) |
| Outstanding Shares | N/A | N/A | 11,409,344 |
Note: The company reported no revenue for the periods presented. Operating expenses consist of Research and Development (R&D) and General and Administrative (G&A) costs.
Material Changes vs. Prior Period
- Expense Growth: Total operating expenses increased by 22% ($596k) for the three months ended Dec 31, 2025, compared to the same period in 2024. For the nine-month period, expenses surged 72% ($5.96 million increase).
- R&D Increase: R&D expenses rose 65% quarter-over-quarter and 79% year-to-date, driven by increased clinical trial and product development costs.
- Stock-Based Compensation: A significant non-cash charge of $3.7 million was recognized in the nine months ended Dec 31, 2025, due to the acceleration of unamortized stock-based compensation following the cancellation of stock options for certain employees and board members.
- Capital Structure: The company significantly increased its share count from 2.5 million (March 31, 2025) to 11.4 million (Dec 31, 2025) through multiple equity financings, including a November 2025 private placement and warrant inducements.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management estimates current cash resources ($9.9 million) are sufficient to fund operations only into the third calendar quarter of 2026. The filing explicitly states that these factors raise "substantial doubt about the Company's ability to continue as a going concern."
- Capital Needs: The company estimates it requires an additional $30 million to $36 million to fund operations through the commercialization of its first indication.
- Regulatory and Clinical Progress: The company completed its first-in-human proof-of-concept study (PoC 1) and initiated a follow-on study (PoC 2) expanding to other visceral cancers. Two new patents were issued in late 2025 covering cardiac tissue treatment.
- Nasdaq Compliance Risk: On January 14, 2026, the company received a deficiency letter from Nasdaq regarding the minimum bid price requirement (stock closed below $1.00 for 30 consecutive days). The company has 180 days to regain compliance or face potential delisting.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, citing a lack of segregation of duties and limited staffing.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "third quarter of 2026" liquidity estimate given the high burn rate ($14M loss in 9 months).
- Dilution Impact: Assess the impact of the 11.4 million outstanding shares and the 10.75 million potentially dilutive warrants on future equity value.
- Nasdaq Status: Monitor the company's progress in meeting the $1.00 minimum bid price requirement by July 13, 2026, to avoid delisting.
- Stock-Based Compensation: Review the $3.7 million one-time charge related to option cancellations to understand the true cash burn rate versus reported net loss.
- Financing Terms: Examine the terms of the November 2025 private placement and warrant inducements for any restrictive covenants or future dilution triggers.